Abstract:Fan Zhang, 1, 2 Yan Han, 1, 2 Liming Zheng, 3 Jianhong Liu, 4 Yunfei Wu, 4 Zuowei Bao, 5 Longgen Liu, 6 Wenjian Li 7 1 Department of Endocrinology, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 2 Department of Clinical Nutrition, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 3 Clinical Laboratory, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 4 Department of Pathology, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 5 Department of Ultrasonography, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 6 Department of Liver Diseases, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China; 7 Department of Urology, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China Correspondence: Longgen Liu, Department of Liver Diseases, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, 300 Lanling North Road, Changzhou, Jiangsu, 213001, People's Republic of China, Tel +86-0519-82009057, Email Wenjian Li, Department of Urology, Changzhou Third People's Hospital, Changzhou Medical Center, Nanjing Medical University, 300 Lanling North Road, Changzhou, Jiangsu, 213001, People's Republic of China, Tel +86-0519-82009011, Email Purpose: The identification of significant fibrosis is critical for predicting the prognosis of non-alcoholic fatty liver disease (NAFLD). This study aimed to compare the predictive value of chitinase-3-like protein 1 (CHl3L1) and other non-invasive biomarkers, as well as to establish a novel non-invasive diagnostic model for assessing the risk of significant fibrosis in NAFLD. Patients and Methods: A total of 71 patients with confirmed NAFLD based on liver biopsy were included in this study. Serum CHI3L1 levels and other non-invasive fibrosis assessment measures were determined. The aspartate aminotransferase-to-platelet ratio index (APRI) and Fibrosis-4 Index (FIB-4) were calculated to assess the diagnostic superiority of serum CHI3L1 compared to other non-invasive fibrosis assessment measures. Multivariate logistic regression analysis was conducted to identify relevant variables for constructing a diagnostic model. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic accuracy of each index, including the area under ROC curve (AUC), sensitivity, and specificity. A nomogram was established based on the logistic regression model. Results: Serum CHI3LI levels were found to be higher in NAFLD patients with significant fibrosis compared to those without significant fibrosis. Multivariate logistic regression analysis revealed that aspartate aminotransferase (AST), type IV collagen (IV-C), CHI3L1, and liver stiffness measurement (LSM) were identified as potential independent risk factors associated with significant fibrosis in patients. The AUC of CHI3L1 for diagnosing significant liver fibrosis was 0.716 (0.596,0.836), with the optimal cut-off point of 125.315. The nomogram incorporating CHI3LI, AST, IV-C, and LSM further improved the potential predictive value, with an AUC for diagnosing significant fibrosis of 0.864 (0.766,0.962). This was superior to IV-C, CHI3L1, LSM, and APRI (all p < 0.05). Conclusion: The diagnostic model constructed by CHI3L1 combined with the existing non-invasive markers AST, IV-C, and LSM can help assess the risk of significant liver fibrosis in NAFLD. Keywords: nonalcoholic fatty liver disease, fibrosis, chitinase 3-like protein 1, liver biopsy, nomogram Nonalcoholic fatty liver disease (NAFLD) is currently recognized as the prevailing chronic liver disease globally. 1 NAFLD can potentially progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 2 A meta-analysis was conducted to comprehensively assess the incidence rate of HCC in different subpopulations of NAFLD patients, with a specific emphasis on the association between NAFLD and liver fibrosis. NAFLD is characterized by the excessive accumulation of fat in the liver and can progress to advanced stages of fibrosis. Moreover, it has been recognized as -Abstract Truncated-

Exosome GLUT1 Derived from Hepatocyte Identifies the Risk of Non-Alcoholic Steatohepatitis and Fibrosis

Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose

Serum Proteomic Analysis Revealed Diagnostic Value of Hemoglobin for Nonalcoholic Fatty Liver Disease

Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

Using Next-generation Sequencing to Identify Novel Exosomal Mirnas As Biomarkers for Significant Hepatic Fibrosis.

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.

Liver-derived Exosomal miRNA in NAFLD: Mechanisms of Action, Biomarkers, and Therapeutic Applications

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Combined and Sequential Non-Invasive Approach to Diagnosing Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease and Persistently Normal Alanine Aminotransferase Levels.

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.

Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy

An novel effective and safe model for the diagnosis of nonalcoholic fatty liver disease in China: gene excavations, clinical validations, and mechanism elucidation

Fasting plasma lactate: A diagnosis and staging biomarker with superior performance in adult nonalcoholic fatty liver disease

The plasma degradome reflects later development of NASH fibrosis after liver transplant

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease

Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD

Association of Non-Invasive Markers with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study